Reversing the New Anticoagulants

Susan C. Lambe, MD
Assistant Clinical Professor
Department of Emergency Medicine
University of California, San Francisco

Disclosure

Roadmap for today
**Roadmap for today**

- Characteristics of novel anticoagulants
- Approach to the bleeding patient
- Specific reversal agents
- UCSF guidelines

**Scope of Problem**

- Prevalence atrial fibrillation
  - 3.03 million in 2005
  - 7.56 million by 2050
- VTE = 900K/yr in US
- 1-2% of adults take warfarin

**Warfarin**

1920s – Outbreak hemorrhagic disease in cattle in northern US and Canada
1933 – Isolated by Karl Link
1948 – Rodenticde
1954 – Approved in humans

**WARF-arin**

*Wisconsin Alumni Research Foundation*  
*Coumarin*, plant molecule in sweet clover
Warfarin Disadvantages
- Bridging
- Drug and food interactions
- Long half-life
- Close monitoring required

Why New Anticoagulants?
- Rapid onset/shorter half-life
- Fewer drug and no food interactions
- No lab monitoring
- Equivalent to warfarin
  - Prevention of stroke, VTE
  - Bleeding rates

New Anticoagulant Disadvantages
- Limited experience treating bleeding
- No proven reversal agent
- No monitoring

What’s in a name?
- Direct Thrombin Inhibitors (DTIs)
- Novel Oral Anticoagulants (NOACS)
- Target Specific Oral Anticoagulants (TSOACS)
Roadmap for today

• Characteristics of novel anticoagulants
• Approach to the bleeding patient
• Specific reversal agents
• UCSF Guidelines

New Anticoagulants

• Dabigatran (Pradaxa®)
• Rivaroxaban (Xarelto®)
• Apixaban (Eliquis®)

Dabigatran Indications

• FDA approved
  • Stroke prevention in non-valvular afib
• Under FDA review
  • VTE prophylaxis in hip or knee replacement
  • Approved in Europe/Canada
Dabigatran Dose

- Stroke prevention
  - 150 mg, po bid
  - Renal insufficiency 75 mg, po bid
- DVT prophylaxis
  - 220 mg, po qd

Dabigatran Mechanism

- Direct Thrombin (Factor IIa) inhibitor
- Blocks conversion of fibrinogen to fibrin

Dabigatran Pharmacology

- Dabigatran etexilate = inactive pro-drug
- Rapidly absorbed
- Active form binds active site of thrombin
- Inhibits free and clot-bound thrombin
Dabigatran Pharmacokinetics

- Predictable
- Rapid onset
- Peak plasma level at 2 hours
- Half-life 14-17 hours

Dabigatran Pharmacokinetics

- No food interactions, few drug interactions
- Fixed dosing can be used
- No need for routine monitoring or dose adjustment

Dabigatran Metabolism

- 85% excreted via the kidneys
- Use caution with renal dysfunction
- Low protein binding
  - Eliminated by hemodialysis

Dabigatran Metabolism

- NOT metabolized by p450 system
- Substrate of efflux transporter P-glycoprotein
  - Inducers (e.g., rifampin) reduce effect
  - Inhibitors (e.g., verapamil) increase effect
Dabigatran Metabolism

- Decreased effect with P-gP inducers
  - Rifampin
- Increased effect with P-gP inhibitors
  - Dronedarone
  - Ketoconazole, Itraconazole
  - Verapamil
  - Amiodarone
  - Quinidine
  - Clarithromycin

New Anticoagulants

- Dabigatran (Pradaxa®)
- Rivaroxaban (Xarelto®)
- Apixaban (Eliquis®)

FACTOR Xa INHIBITORS

Rivaroxaban (Xarelto®) Apixaban (Eliquis®)

Indications

- Rivaroxaban/Apixaban
  - Stroke prevention in non-valvular atrial fib
- Rivaroxaban only
  - VTE prophylaxis post-joint replacement
  - DVT/PE prophylaxis and treatment
**Rivaroxaban and Apixaban Dose**

- **Non-valvular afib**
  - Rivaroxaban, 20 mg po qd
  - Apixaban, 5 mg po qd
- **DVT/PE**
  - Rivaroxaban, 15 mg po qd
- **DVT prophylaxis**
  - Rivaroxaban, 10 mg po qd

**Rivaroxaban and Apixaban Mechanism**

Selective, direct, factor Xa inhibitors

**Rivaroxaban and Apixaban Pharmacology**

- Highly protein bound
- Not easily dialyzed
- Few drug interactions

**Rivaroxaban and Apixaban Pharmacokinetics**

- Similar to dabigatran
- Predictable
  - Not affected by age, sex, body weight
  - Fixed dose
- Peak at 2 – 3h
- Half life 7-14h
Metabolism

Rivaroxaban
- Excretion
  - 2/3rd renal
  - 1/3rd liver
- Dose adjusted for reduced CrCl

Apixaban
- Excretion
  - 2/3rd liver, biliary
  - 1/3rd renal

Coagulation Assays

Dabigatran
- Peak/trough 20-300 ng/ml
  - aPTT
    - Prolonged at >50 ng/ml
    - Normal at 25 ng/ml
  - Thrombin time
    - Prolonged at 3 ng/ml
    - Normal at 1 ng/ml

Dabigatran
- aPTT not useful
- Thrombin time
  - If normal, dabigatran not present

Coagulation Assays

- Not routinely necessary
- Indications
  - Major bleeding
  - Overdose
  - Emergent surgery
Coagulation Assays

Rivaroxaban/Apixaban
- Peak/trough 25-400 ng/ml
- aPTT
  - Prolonged at 120 ng/ml
  - Normal at 60 ng/ml

Coagulation Assays

Rivaroxaban/Apixaban
- Anti-factor Xa assay
  - No assay for rivaroxaban available
  - Ask for assay calibrated for enoxaparin
  - Estimate of rivaroxaban/apixaban activity

Roadmap for today
- Characteristics of novel anticoagulants
- **Approach to the bleeding patient**
- Specific reversal agents
- UCSF guidelines

Approach to Bleeding
- Discontinue anticoagulant
- Compress
- Fluid replacement, transfusion
Approach to Bleeding
Consider emergent reversal
- Intracranial
- Pericardial
- Intraspinal
- Hemorrhagic shock
- Drug overdose
- Emergency surgery

Roadmap for today
- Characteristics of novel anticoagulants
- Approach to the bleeding patient
- Specific reversal agents
- UCSF guidelines

Reversal Agents
NO ROLE FOR VITAMIN K IN REVERSAL OF NEW ORAL ANTICOAGULANTS

Reversal: Options
- Hemodialysis (dabigatran only)
- Prothrombin complex concentrate (PCC)
- Recombinant Factor VIIa (rFVIIa)
- aPCC (FEIBA®)
**Reversal: Hemodialysis**

For reversing dabigatran

Evidence
- 6 healthy volunteers w ESRD
- 62% removed after 2 hours
- 68% removed after 4 hours

Rivaroxaban/apixaban too highly protein-bound for HD

Stangier, 2010

---

**Reversal: PCC**

Two preparations
- Kcentra® 4-factor PCC (II, VII, IX, X)
- Bebulin® 3-factor PCC (II, IX, X)

---

**Reversal: Specific Agents**

Human studies
Animal studies
Specific Antidotes

---

**Reversal: Specific Agents**

Human studies
Animal studies
Specific Antidotes
Reversal: Specific Agents

Human studies
- 5 studies, 2011-2013
- Healthy volunteers
- Anticoagulants: dabigatran, rivaroxaban, apixaban
- Reversal agents
  - PCC
  - aPCC
  - rFVIIa
- Outcome: clotting assays

Reversal: Human Studies

Erenberg, 2011
- Study design
  - N=12 subjects
  - Dabigatran or rivaroxaban po x 2.5 d
  - Treated with PCC bolus iv
  - Measured PT and ETP over 24 hours

Reversal: Human Studies

Erenberg, 2011
- Findings
  - PCC reversed PT, ETP in rivaroxaban treated patients
  - PCC did not reverse dabigatran

Reversal: Human Studies

Marlu, 2012
- Study design
  - N=10 men
  - Dabigatran or rivaroxaban po x 1
  - Collected blood samples
  - Treated blood (PCC, rFVIIa, aPCC)
Reversal: Human Studies

Marlu, 2012
- Findings
  - Dabigatran
    - rFVIIa most effective
  - Rivaroxaban
    - PCC most effective

Reversal: Human Studies

Khoo, 2013
- Dabigatran+aPCC
- Study design
  - N=8 subjects on dabigatran
  - Blood treated with aPCC

Reversal: Human Studies

Khoo, 2013
- Findings
  - aPCC reversed dabigatran

Reversal: Human Studies

Dinklaar, 2013
- Rivaroxaban+PCC
- Study Design
  - N=9 subjects
  - PCC added to rivaroxaban-treated samples
  - Coagulation assays performed
Reversal: Human Studies

Dinklaar, 2013
- Rivaroxaban + PCC
  - Findings – mixed results
    - PCC
      - Normalized thrombin generation
      - Did not normalize PT
    - Dose of PCC required depended on type of assay

Reversal: Human Studies

Korber, 2013
Rivaroxaban + PCC/rVIIa
- Study design
  - N=10 subjects
  - Blood samples treated with rivaroxaban
  - Added PCC and rVIIa
  - Performed clotting assays

Reversal: Human Studies

Korber, 2013
Rivaroxaban + PCC/rVIIa
- Findings
  - PCC had no effect on clotting tests
  - rVIIa reversed PT and clotting factor time prolongation

Human Studies: Summary

Dabigatran
- Reversed with aPCC in 2/2 studies
Rivaroxaban
- Reversed with PCC in 3/4 studies
Human studies: Limitations

- Variable designs
- Healthy volunteers
- Reversal agents added to blood samples
- Clotting tests proxy for bleeding

Reversal: Specific Agents

**Human studies**

**Animal studies**

Specific antidotes

Reversal: Animal studies

- 6 studies, 2008-2013
- Anticoagulants:
  - Dabigatran
  - Rivaroxaban
  - Apixaban

- Reversal agents
  - PCC
  - rFVIIa
  - aPCC (FEIBA®)
  - Fibrinogen
  - FFP

- Outcomes
  - Clotting assays
  - Bleeding

Reversal: Animal Studies

Van Ryn, 2008

- Study Design
  - Rats infused w high dose dabigatran x 20 min
  - Reversed with rFVIIa and aPCC (FEIBA®) given iv
  - Bleeding measured 5 min after tail incision
Reversal: Animal Studies

Van Ryn, 2008
- Findings
  - Both agents reduced bleeding time
  - Neither agent reduced blood loss

Reversal: Animal Studies

Zhou, 2011
- Study Design
  - Mice were treated with dabigatran po
  - ICH induced
  - Reversed with intravenous
    - PCC
    - Murine FFP
    - rFVIIa

Reversal: Animal Studies

Zhou, 2011
- Findings
  - N=96 mice
  - PCC prevented hematoma expansion
  - Murine FFP worked only with high dose dabigatran
  - rFVIIa did not prevent hematoma expansion

Reversal: Animal Studies

Godier, 2012
- Study Design (n=83 rabbits)
  - T=0 min, rivaroxaban iv
  - T=1 min, procoagulant iv (PCC, rFVIIa)
  - Hepatosplenic bleeding induced
  - T=15 min, total blood loss recorded
Reversal: Animal Studies

Godier, 2012
- Findings
  - Neither rFVIIa nor PCC reduced total blood loss

Reversal: Animal Studies

Pragst, 2012
- Study Design (n=28 rabbits)
  - T=0 min, dabigatran iv
  - T=5 min, PCC infusion
  - T=10 min, kidney incision

Reversal: Animal Studies

Pragst, 2012
- Findings
  - PCC reduced blood loss, bleeding time
  - Dose dependent

Reversal: Animal Studies

Perzborn, 2013
- Study Design – rats
  - T=0 min, rivaroxaban iv
  - T=5 min, bleeding induced
  - T=6 min, reversal iv (PCC, aPCC, rFVIIa)
Reversal: Animal Studies
Perzborn, 2013
- Findings – rats
  - n=7-12/group
  - All agents reduced bleeding time
    - PCC
    - aPCC
    - rFVIIa

Reversal: Animal Studies
Perzborn, 2013
- Study Design – baboons (n=7)
  - T=0 min, rivaroxaban infusion
  - T=30 min, reversal agent
  - Experimental forearm incision
  - Bleeding time measured

Reversal: Animal Studies
Perzborn, 2013
- Findings
  - aPCC and rFVIIa both reduced bleeding time
    - aPCC – from twice normal to normal
    - rFVIIa – from 2.5 normal to 1.7 normal

Reversal: Animal Studies
Martin, 2013
- Study design
  - T=0, simultaneous apixaban bolus and reversal agent bolus
  - T=20 min hepatosplenic section
  - T=30 min, blood loss measured
Reversal: Animal Studies

Martin, 2013

- Findings
  - rFVIIa partially corrected bleeding time
  - PCC, rFVIIa, fibrinogen did NOT reverse blood

Summary of Animal Studies

Dabigatran
- PCC reversed dabigatran in 3/3 animal studies

Rivaroxaban and Apixaban
- PCC, aPCC, rFVIIa reversed rivaroxaban in 1/3 studies

Animal Studies: Limitations

- Wide variability in study design
  - Different doses
  - Different species
  - Different outcomes (coagulation assays, bleeding time, blood loss)
- Human clotting factors behave differently in non-humans

Reversal: Specific Agents

Human studies
Animal studies
Specific antidotes
Reversal: Specific Antidotes

- r-Antidote (PRT064445)
- aDabi-Fab
- PER977

Lu, 2013

Reversal: Specific Antidotes

r-Antidote (PRT064445)

- Antidote for rivaroxaban
- Recombinant protein
- Binds Xa inhibitor site
- Reduced blood loss in animal models
- Not tested in humans

Lu, 2013

Reversal: Specific Antidotes

aDabi-Fab

- Monoclonal antibody
- Antidote for dabigatran
- Reversed anticoagulant assays in rats

Schiele, 2013

Reversal: Specific Antidotes

PER977

- Small synthetic molecule
- Directly binds Xa and IIa
- Reverses dabigatran, rivaroxaban, apixaban

Laulicht, 2012
Summary Specific Antidotes

- Three promising agents
- None FDA-approved in humans yet

Roadmap for today

- Characteristics of novel anticoagulants
- Approach to the bleeding patient
- Specific reversal agents
- UCSF guidelines

Caveat:

No proven reversal agents or antidotes
UCSF Guidelines

General Principles
- Discontinue drug
- Hemostasis
- Hemodynamic support
- Reverse other antithrombotic drugs

Consider
- Hemodialysis (dabigatran only)
- Activated charcoal

If other measures fail
- Assess thrombotic risk
- In past 6 wks
  - MI
  - CVA, TIA
  - DVT/PE
  - Severe PVD

If all measures fail
- aPCC (FEIBA®) to reverse dabigatran
- PCC (Kcentra®) to reverse rivaroxaban/apixaban
FEIBA® and Kcentra® Cautions

- Increase risk of thromboembolism
- Reversal is OFF-LABEL
  - Weigh risk/benefit
- Blood products
  - Kcentra® contains heparin

Roadmap for today

- Characteristics of novel anticoagulants
- Approach to the bleeding patient
- Specific reversal agents
- UCSF guidelines